Airbus A380 to Stop Production… Officially

The European aerospace group said it had made the “painful” decision to stop making A380 after Emirates, the biggest customer, reduced an outstanding order for 53 planes to only 14. [The Guardian]

Airbus announcement on February 14 – capital market liked it.

A History

A380 is the world’s largest passenger airliner, a wide-body aircraft manufactured by Airbus. The project was announced in 1990 to challenge the dominance of the Boeing 747.

Source: The Guardian

Boeing’s 747 project had its origin in a US Air Force requirement for a large heavy-lift transport carrying up to 750 troops over long distances. Losing that contract, however, made Boeing to pursue it in high-capacity commercial jet transportation. [Air Force One, the presidential aircraft version of the 747 will be modified based on 747-8; Boeing received the contract in July 2018 – a $3.9 billion contract to build two, due to be delivered by December 2024]

Boeing’s board of directors decided to launch the 747 in March 1966, making its decision public in April, along with an announcement that Pan Am had placed its first order for 25 at $20 million each. First flown commercially in 1970 with Pan American Airways, the 747 held the passenger capacity record for 37 years.

Conceived as a response to the Boeing 747, the Airbus A380 development program was officially launched in June 1994. It is the largest jet airliner ever built and is the world’s first double-deck passenger aircraft. First flight took place from Toulouse, France on 27 April 2005, A380 completed its first commercial with Singapore Airlines on October 25th 2007 with 471 passengers on board (breaking 747’s record).

Commercial Success?

A380 took the realm and record in terms of manufacturing and engineering, but is often considered an unsuccessful commercial product. As of January, Airbus had received 313 firm orders for the passenger version of the plane, of which 234 had been delivered.

A380 O&D as of Jan 2019| Source: wikipedia

But its target was to sell 700 in total. The whole programme is thought to have cost $25bn (£19.4bn). [BBC]

Consumers like A380 but not airlines do not

The average price of Boeing’s 747-8 as of January 2018 is at $402.9 million and $403.6 million for the passenger and freighter version respectively. The current list price is up 4% at $418-419 million.

The average list price of the Airbus A380 is 10% more expansive, based on its 2018 average list price of $445.6 million.

Common concerns and considerations…

  • too large, hard to fill and thus inefficient
  • high fuel prices, high operating cost and environmental concerns
  • airlines looking at Boeing’s new family of 777s

Now, the world’s largest passenger airliner will not be produced after 2021.

The Economics

The rising global demand in the 21st century is the underlying theme, especially the rapidly rising number of air travelers in the Asia and Middle East market.

The center of Airbus’ pitch for the A380 in the early 2000s was the notion that the core of the long haul business model would be so-called hub-to-hub flights. [AirwaysMag]

On the other hand, Boeing is pursing the point-to-point (more accurately hub-to-spoke) thesis.

Boeing’s 777X, specifically the larger 777-9X variant, offers similar performance (the A380 can fly slightly further) to the A380. And pretty much every other carrier with a hub network large enough to support an A380 has ordered either the Boeing 777X or the Airbus A350. [AirwaysMag]

The airline industry is planned and started as fragmented. Then comes bankruptcy and consolidation.

And airlines are also sharing world hubs or exploring second/third tier cities. (it’s not common for a single airline to secure the majority share of an international traffic hub – which would make A380 a wise choice/investment)

Airbus may have bet that countries like China and India will have large demand centered around one or two cities. But the reality is the opposite. They have planned ahead to spread out and made several international hubs.

First tier airports/cities in terms of size will add new members to its list. That’s how the predicted increase in demand mostly absorbed.

Smart Building (1): Data + Management Startups Roundup

Smart building is a hot topic and will be at the center of future real estate, a $217 trillion giant industry.


So what is the core segments of smart building? This blog will provide a roundup of startups in the data + management space.


Comfy (developed by Building Robotics)

Probably most famous for its collaboration with WeWork in 2016, Comfy is an app that lets users to adjust the temperature, lights etc. in the office from smartphones.

Comfy app | Source: comfyapp.com

Plus a data analysis and insights tool for office managers.

Comfy app | Source: comfyapp.com

The company was founded in 2012, raised Seed & Series A from Claremont Creek Ventures and other investors including the Westly Group. In 2016, shortly before the WeWork collaboration, a Series B of $12 million was raised. Then in 2018, Building Robotics was acquired by Siemens (in a series of acquisitions) for an undisclosed amount.

Euclid

Euclid is a leading spatial-analytics platform based in San Francisco. With fundings from NEA, Benchmark and other investors, It has built a proprietary analytic offering that uses WiFi signals to understand how space is used without the installation of any additional hardware. It can track the identity and behavior of people in the physical world.

A retailer application of Eculid’s technology | Source: marketingland.com

In Feb 2019 (a few days ago), Euclid was acquired by WeWork (“The We Company”). The blog post from The We Company.

Teem

A maker of office management software, Teem was acquired by WeWork in Sep 2018 for around $100 million. Teem has grown from a conference room management tool to include office space management, (office) room display, visitor management, etc.

Booking | Source: teem.com
Display | Source: teem.com
Visitor check-in | Source: teem.com
BuildingIQ

An energy-efficiency focused startup, BuildingIQ listed on Australian Securities Exchang and raised A$20 million in 2015, with an IPO marketcap of A$85 million.

Back in 2013, it raised $9 million from Aster Capital (backed by Schneider
Electric, Alstom and Solvay), the Venture Capital unit of Siemens Financial Services (SFS VC) and Paladin Capital.

BuildingIQ Mobile App | Source: buildingiq.com/app

In 2018, BuildingIQ acquired Buildingsense, another building data analysis company in Australia.

Flywheel

Formerly known as SCIenergy, Flywheel is a maintenance (task) & energy management startup based in Dallas. Invested by DFJ, Flywheel raised its latest round in 2014 by a group of energy focused funds, led by Braemar Energy Ventures and joined by the Westly Group and others.

Source: flywheelbi.com
Source: flywheelbi.com

Consolidation is coming faster than most could imagine…

Apple’s Service Bundle

Apple may know well before the investors that their flagship iPhone would face a slowdown and it needs new growth strategies.

[Read more on iPhone’s sluggish sales and challenges  & its recent pricing strategy]

Apple has talked about its services for a while and it’s not limited to Apple Care or Genius Bar (“Physical Services”), but more about Distribution Services.

System/Platform Level

I guess the most obvious change happened in 2016 when a new revenue sharing scheme was introduced by Apple – from a 30% cut to a 15%-cut-after-first-year. And other features were included such as “subscription group“… marching into subscription-based services revenue model.

85% net revenue after first year | Source: verge.com

Apple News

Apple News | apple.com

Available in Australia, UK, and US, it’s currently a curated display place for publisher subscriptions. It could be developed into a Toutiao-like app for personalization and could be complimentary with Apple’s Stock app.

And it won’t be surprised to me that in the future you can trade stocks through this app – probably by upgrading to a premium version with other complementary benefits (like news/reports).

Apple Music

Anyway, music is where Apple found its turnaround with iTunes and iPod. Plus, it is the most explored region with established companies and new entrants.

Apple Music Subscription | Source: apple.com

Spotify Premium – $9.99 / month

Spotify Subscription | Source: spotify.com/us/premium

YouTube Music – $9.99/month

Youtube Music Subscription | Source: youtube.com/musicpremium

Pandora Plus – $4.99/month & Premium – $9.99/month

Pandora Subscription | Source: pandora.com

Apple TV & Streaming Channel

Apple has long reported to be interested in contents distribution especially video. And rumors about an acquisition of Netflix didn’t come from nowhere.

A New York Times report back in March 2018.

A CNBC report in October 2018 – Apple plans to give away original content for free to device owners as part of new digital TV strategy.

Apple has cash and ability for original contents (and can acquire/build a studio). Apple has educated customer base (thanks for Netflix). Apple has introduced Clip for iOS short videos (think about Snapchat and Douyin, plus its ability in music and messaging). Apple has AppleTV and AirPlay.

Apple TV App | Source: apple.com

There are just too many things to do in this space, broadly speaking.

And the competition is fierce. Netflix, Amazon Prime Video, Youtube TV, Facebook/Instagram TV, Disney/Hulu, AT&T/HBO…

And the AR/VR future…

Let’s see.

Gaming

It might be something new. But Apple could introduce a monthly plan to play most iOS games freely (with some exceptions maybe). Just like what Tencent did with WeChat Read – subscriptions that can read all books on its app.

Let’s see what Steam will do… Steam has subscription-based products, although not a bundle.


A master bundle plan for Apple users in the future? Possible.

 

Novel FDA Approvals

Since the new FDA Commissioner Dr. Scott Gottlieb was sworn in on May 11, 2017, the traditionally cumbersome regulatory body has shown an unprecedented embracement for novelty in treatments and beyond.

Overarching guidelines:

Here is a roundup of those approvals

Novartis, Kymriah, first gene (transfer) therapy (first CAR-T) available in the United States

  • August 30, 2017
  • Biologics License Application (BLA) submitted on February 2, 2017
  • Approval basis: the safety and efficacy of Kymriah were demonstrated in one multicenter clinical trial of 63 pediatric and young adult patients with relapsed or refractory B-cell precursor ALL. The overall remission rate within three months of treatment was 83 percent. (FDA statement)

Pear Therapeutics, the Reset app, first mobile application to treat substance use disorders (SUD)

  • September 14, 2017
  • de novo premarket review pathway
  • Technology: the device delivers cognitive behavioral therapy to patients to teach the user skills that aid in the treatment of SUD and are intended to increase abstinence from substance abuse and increase retention in outpatient therapy programs. The system is intended to be used in conjunction with outpatient therapy and in addition to a contingency management system, a widely-used program for treating SUD that uses a series of incentives to reward patients for adherence to their treatment program.
  • Approval basis: a multi-site, unblinded 12-week clinical trial of 399 patients who received either standard treatment or standard treatment with the addition of a desktop-based version of Reset which could be accessed at the clinic or at home. The data showed a statistically significant increase in adherence to abstinence for the patients with alcohol, cocaine, marijuana and stimulant SUD in those who used Reset, 40.3 percent, compared to the patients who did not, 17.6 percent. The clinical trial did not demonstrate the effectiveness of using the Reset device in patients reporting opioids as their substance of abuse. (FDA statement)
reSET app | Source: New York Times

Memorial Sloan Kettering Cancer Center,  IMPACT test, first tumor-profiling laboratory-developed test to receive authorization through the FDA

  • November 15, 2017
  • de novo premarket review pathway
  • Technology: the IMPACT test uses next-generation sequencing (NGS) to rapidly identify the presence of mutations in 468 unique genes, as well as other molecular changes in the genomic makeup of a person’s tumor.
  • Approval basis: results indicated that the assay is highly accurate (greater than 99 percent) and capable of detecting a mutation at a frequency of approximately 5 percent (range of 2-5 percent). Additionally, detection of certain molecular changes (microsatellite instability) using the IMPACT test was concordant more than 92 percent of the time across multiple cancer types in 175 cases, when compared to traditional methods of detection.
  • Along with this authorization, the FDA is also establishing a Class II regulatory pathway for the review of other NGS-based tumor profiling tests for use in patients diagnosed with cancer. Class II designation allows these types of tests to be eligible to use the FDA’s 510(k) clearance process, either by submitting the application. (FDA statements)
Source: mskcc.org

Proteus Digital Health x Otsuka Pharma, Abilify MyCite, first drug in the U.S. with a digital ingestion tracking system

  • November 13, 2017
  • New Drug Application (NDA) dated and received June 26, 2015
  • Technology: the system works by sending a message from the pill’s sensor to a wearable patch. The patch transmits the information to a mobile application so that patients can track the ingestion of the medication on their smart phone. Patients can also permit their caregivers and physician to access the information through a web-based portal.
  • Approval basis: Abilify was first approved by the FDA in 2002 to treat schizophrenia. The ingestible sensor used in Abilify MyCite was first permitted for marketing by the FDA in 2012. (FDA statement)
Source: npr.org

Spark Therapeutics, Luxturna, first (directly administered) gene therapy approved in the U.S. to target a disease caused by mutations in a specific gene

  • December 19, 2017
  • Biologics License Application (BLA) dated April 26, 2017, and received May 16, 2017
  • Approval basis: The efficacy of LUXTURNA in the Phase 3 study was established based on the multi-luminance mobility test (MLMT) score change from baseline to one year. LUXTURNA Phase 3 clinical study results showed a statistically significant difference between the intervention group (n=21) and control participants (n=10) at one year in median bilateral MLMT score change (intervention minus control group difference of 2; p=0.001) and median first-treated eye MLMT score change (intervention minus control group difference of 2; p=0.003). (Spark press release)
  • FDA statement
Luxturna | Source: Spark Therapeutics

Loxo Oncology, Vitrakvi, first time that an entirely new treatment has received a tumor-agnostic indication at its initial approval

Source: genengnews.com

Apple, the ECG app (with Apple Watch), first FDA clearance for retail ECG watch technology

  • September 11, 2018
  • De Novo clearance from the Center for Devices and Radiological Health, classified as Class II under the generic name electrocardiograph software for over-the-counter use
  • Technology: the ECG app determines the presence of atrial fibrillation (AFib) or sinus rhythm on a classifiable waveform
  • FDA statement
  • FDA letter to Apple
  • covered in a previous blog: New Era of Medical Grade Consumer Device
Apple Watch Series 4, the ECG app | Source: Apple
  • January 17, 2019 update: Alphabet’s life sciences unit Verily received 510(k) clearance from FDA as a Class II medical device for its on-demand ECG feature
Study Watch | Source: Verily

 

Current Anti-Aging Startups Roundup

Anti-aging is a centuries-long problem and we don’t have an answer.

Here is a summary of current notable efforts that might provide some sort of solution.

Biopharma/Therapeutics Approach

Unity Biotechnology – eliminate senescent cells
Source: Unity Cellular Senescence Investor & Analyst Presentation on Dec. 11, 2018
  • Lead candidate UBX0101, a first-in-class senolytic molecule
  • UBX1967
    • January 2019, completed license agreement with Ascentage Pharma, granting Unity the exclusive worldwide development and commercialization rights and non-exclusive manufacturing rights outside of Greater China (China, Hong Kong, Macau and Taiwan) for UBX1967 in all non-oncology indications. Inside Greater China, UNITY is obligated to commercialize UBX1967 through a joint venture with Ascentage Pharma. The UBX1967 License Agreement also grants UNITY the right to continue its preclinical development efforts with respect to another Ascentage Pharma-controlled Bcl-2 inhibitor compound that will serve as a back-up to UBX1967.
    • Per the 2016 pact, should Unity choose to license at least one more products, the Chinese biotech will gain a total of 1,333,338 shares
    • plans to file an IND application for UBX1967 in the second half of 2019
Calico – A previous google company
  • Founded in 2013, Calico started within Google (later Alphabet) and soon jump-started with huge fundings – a $1.5 billion initiative/collaboration in September 2014 with Abbvie. “AbbVie and Calico will each initially provide up to $250 million to fund the collaboration with the potential for both sides to contribute an additional $500 million.”
  • In June 2018, the collaboration was extended with another $1 billion. “AbbVie and Calico will each commit to contribute an additional $500 million to the collaboration.”
  • It was also cited that “since 2014, the collaboration between the two companies has produced more than two dozen early-stage programs addressing disease states across oncology and neuroscience and yielded new insights into the biology of aging.”
samumed
Napa Therapeutics

Data Approach

Juvenescence AI
  • A subsidiary of Juvenescence, a joint effort of Juvenescence + Insilico Medicine
  • Formed in July 2017
Human Longevity
  • Was valued at $1.6 billion in 2017 with fundings from Celgene, Illumina, GE Ventures, etc.
  • Declined to a valuation of $310 million according to a WSJ report

Portfolio Approach

Juvenescence
Life Biosciences
  • Jan. 2019 Series B of $50 million
  • co-founded in 2017 by David Sinclair and Tristan Edwards
  • 8 Subsidiaries
    • Prana Biotechnology (an initial $7.5 million investment in Jan.2019)
    • Lua, HIPAA-compliant medical technology platform (acquired in Oct. 2018)
    • Senolytic Therapeutics acquired at a very early stage
    • Jumpstart Fertility acquired at a very early stage
    • the other four were formed in-house (Selphagy Tx, Spotlight Biosciences, Continuum Biosciences, Animal Biosciences)

Somehow, reminded me of Theranos… also an area that might not be reguated by FDA… (Ageing is not a disease by FDA’s definition) and some are backed by non-traditional biotech VC firms… But most seemed to be more experienced and sophisticated in biology and medicine (than Theranos’ average).

Trees and Global Warming

Planting trees seems to be one of the most common and economic solution to reduce CO2 and is well-recognized around the globe. It is also one of the “negative-emissions technologies” to help meet Paris Agreement targets – afforestation and reforestation.

However, climate changes are not that simple and global temperature won’t be restored just by planting trees.

Clearly, we have omitted some “negative impacts” of trees since the beginning. More efforts are definitely needed to plant trees more effective.

One of the problems is “albedo effect”. Tree leaves absorb more sunlight than do other types of land cover. Forests can reduce Earth’s surface albedo, meaning that the planet reflects less incoming sunlight back into space, leading to warming. (Nature)

Also, trees themselves are emitting CHand N2O, greenhouse gases.

Source: Nature

The question, raised on New York Times with Prof. Unger at Yale in 2014, had previously attracted lots of debates.

I think it is more or less similar to companies’ earnings projection. Before launching a new product, earnings projection looks great. But it is often overestimated. Other cost items will appear, leaving the product a thinner margin.

Trees are the same. Simply planting trees probably won’t give us the estimated benefits. While I believe the “net effect” is good, we do need more sophisticated understanding and solutions regarding trees.

 

US Government Shutdown – an Incomplete List of Direct Effects in Business

On Jan 10, Fed Chair Jerome Powell commented at the Economic Club about government shutdown…

In the short term, if government shutdowns don’t last very long, they have typically not left much of a mark on the economy… A longer shutdown is something we haven’t had. If we have an extended shutdown, and I do think that that would show up in the data pretty clearly,… we would have a less clear picture into the economy if it were to go on much longer.

Here is an incomplete list of effects in business…

Saudi Arabia: Surplus to Deficits, Turnaround, Diversification

Saudi Arabia’s financial situation has been closely linked to oil prices.

Saudi Arabia Oil and Non-oil revenues 2012 to 2016 | Source: Saudi Arabia Ministry of Finance statement about the national budget for 2017

The majority of the revenue is from oil exports. Its oil revenue has decreased more than 50% due to the oil price slump in 2014.

Oil comprises 30-40 percent of the real GDP of Saudi Arabia.

Saudi understood the need to diversify decades ago. It became more serious after the 2014 oil price shock. But that means more expenditure and efforts to push for the economic reform.

A “Vision 2030” was announced in 2016. (original English copy)

While expenditure kept increasing, Saudi government has quickly generated its deficits since 2014. Deficit in 2015 is at a similar level of its surplus in 2012 – a SAR 740 billion difference in 3 years. And debts are accumulated quickly.

Saudi has planned to eliminate its deficit by 2023, which could be easily done if oil price maintains.

In Dec 2018, Saudi released its budget of 2019, which includes an expenditure of over SAR 1 trillion and a deficit of ​SAR 131 billion.

While the sixth straight deficit is not something to worry about, the real question is to what level Saudi can diversify its economy and becomes a sustainable nation even without oil. (the contribution of non-oil revenues to total revenues up from 12% in 2014 to 32% in 2018)

Lowered iPhone Sales Forecast and More

Since Apple announced that it would stop reporting the iPhone unit sales number during Q3 earnings call, things have not become easier.

iPhone Ban in China

The fight between Qualcomm and Apple has led to a sales ban on older iPhone models in China, ordered from a Chinese court (福州市中级人民法院). The case was filed against Apple in China in late 2017, saying the iPhone maker infringed patents on features related to resizing photographs and managing apps on a touch screen.

Apple said it planned a software update that would solve the issue; also, the ban would likely take time to enforce, according to Reuters.

iPhone Ban in German

In German, Apple will be pulling iPhone 7 and iPhone 8 models from its stores there following a win for Qualcomm in the District Court of Munich, which ruled that Apple’s devices were infringing on Qualcomm’s intellectual property related to power savings in smartphones. (The Verge)

Qualcomm said on Thursday (Jan.3) that it posted security bonds of 1.34 billion euros ($1.52 billion) to enforce the German court order.

Apple Outlook Cut Citing Weaker iPhone Demands in China

On Jan 2, a letter from Apple CEO Tim Cook to investors said sales will be about $84 billion in the quarter ended Dec. 29, down from earlier estimates of $89 billion to $93 billion. Apple posted sales of $88.3 billion in the fiscal first quarter a year earlier, so the new forecast would mean Apple is reporting a holiday quarter slowdown for the first time since Cook became CEO in 2011. (Bloomberg)

Apple shares fell 10% to $142.19, the biggest drop in almost six years, the next day.

In the letter, Cook said Apple’s gross margin will be approximately 38%. (also discussed in a previous post about Apple’s pricing strategy)

Chinese Phone Makers Gaining In Zero-growth Market

Although 2018 Q4 numbers are not yet available, Q3 numbers tell the same story. According to IDC Quarterly Mobile Phone Tracker on Nov 1.

Company 3Q18 Shipment Volumes (millions) 3Q18 Market Share 3Q17 Shipment Volumes (millions) 3Q17 Market Share 3Q18/3Q17 Change
Samsung 72.2 20.3% 83.3 22.1% -13.4%
Huawei 52.0 14.6% 39.1 10.4% 32.9%
Apple 46.9 13.2% 46.7 12.4% 0.5%
Xiaomi 34.3 9.7% 28.3 7.5% 21.2%
OPPO 29.9 8.4% 30.6 8.1% -2.1%
Others 119.9 33.8% 149.8 39.6% -19.9%
Total 355.2 100.0% 377.8 100.0% -6.0%

And in Gartner’s December report

Vendor 3Q18 Units (thousands) 3Q18 Market Share (%) 3Q17 Units (thousands) 3Q17 Market Share (%)
Samsung 73,360.1 18.9 85,605.3 22.3
Huawei 52,218.4 13.4 36,501.8 9.5
Apple 45,746.6 11.8 45,441.9 11.8
Xiaomi 33,219.7 8.5 26,853.2 7.0
OPPO 30,563.4 7.9 29,449.2 7.7
Others 153,960.0 39.6 159,742.0 41.6
Total 389,068.2 100.0 383,593.4 100.0

What is good for Apple…

From Cook’s letter, we know Apple’s wearables sales grew by almost 50% year-over-year, as Apple Watch and AirPods were wildly popular among holiday shoppers.

Loxo and Pan-Cancer Treatments

In the first week of 2019, besides the BMS-Celgene merger, the $8 billion acquisition of Loxo Oncology by Eli Lilly is the largest deal announced.

For a premium of 68%, what is special with Loxo?

Its approval of Vitrakvi in Nov 2018 is definitely a remarkable one, marking the second approval by the FDA based on a patient’s tumor’s molecular information (TRK fusion), regardless of the location of the tumor within the body. (pancan)

That has been the trend since targeted therapies were proved to be extraordinarily effective in certain types of cancer, usually characterized by gene mutations. EGFR is probably the most famous one.

But FDA approvals were still linked to the tumor locations until May 2017 when Merck’s Keytruda was approved upon a biomarker – microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

Before Keytruda became the first cancer treatment for any solid tumor with a specific genetic feature, it had been approved for the treatment of certain patients with metastatic melanoma, metastatic non-small cell lung cancer, recurrent or metastatic head and neck cancer, refractory classical Hodgkin lymphoma, and urothelial carcinoma.

Loxo’s Vitrakvi, however, received its approval solely based on biomarkers since the beginning. Also, Vitrakvi is the first targeted therapy to be approved this way.

And this big step forward for precision medicine is now acquired by Eli Lilly.

Source: Bloomberg